Top
Cigna Health Services Business Pioneers an Innovative Solution to Affordably Bring Life-Changing Therapies to Patients - Healing Genes
2393
post-template-default,single,single-post,postid-2393,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2078

Cigna Health Services Business Pioneers an Innovative Solution to Affordably Bring Life-Changing Therapies to Patients

Share on facebook
Share on google
Share on twitter
Share on linkedin

Breakthrough, potentially life-changing medicines offer great promise for patients and their families. However, the high prices of the medicines – millions of dollars in some cases – threaten coverage and access by patients who may benefit.

Today, Cigna’s health services business is introducing Embarc Benefit ProtectionSM, a new offering that brings together the health services, medical management and specialty pharmacy expertise of Express Scripts, eviCore, Accredo and CuraScript SD to make breakthrough medicines more affordable and ensure access for those who need it.

Consumers will have no out of pocket payments related to the cost of the medicine and will receive personalized and expert care to assist them through their health journey.

Those who provide health coverage for millions of Americans, such as employers, health plans and unions, will have the peace of mind that comes from being better protected against the high price shocks associated with new breakthrough therapies.

Luxturna™ (voretigene neparvovec-rzyl), the first FDA-approved prescription gene therapy for people with inherited retinal disease, and Zolgensma® (onasemnogene abeparvovec-xioi), a gene therapy for children under 2 years old with spinal muscular atrophy, will be the first two therapies included in the Embarc Benefit Protection solution. Additional therapies may be added in the future.

Read the full story here: https://www.cigna.com/newsroom/news-releases/2019/cigna-health-services-business-pioneers-an-innovative-solution-to-affordably-bring-life-changing-therapies-to-patients

More to explorer

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader

CRISPR treatment inserted directly into the body for first time

A person with a genetic condition that causes blindness has become the first to receive a CRISPR–Cas9 gene therapy administered directly into their body. The treatment is part of a landmark clinical trial to test the ability of CRISPR–Cas9 gene-editing techniques to remove mutations that

No Comments

Sorry, the comment form is closed at this time.